Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Semaglutide and Liraglutide — mechanism, dosing, side effects, legal status, and pricing.
Semaglutide is an FDA-approved GLP-1 receptor agonist used to treat type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It has become one of the most widely prescribed medications for obesity due to its significant weight-loss efficacy.
Liraglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Victoza, 1.8 mg daily) and chronic weight management (Saxenda, 3.0 mg daily). It was the first GLP-1 agonist approved for obesity treatment and paved the way for semaglutide and tirzepatide.
Semaglutide
Liraglutide
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
The STEP clinical trial program demonstrated average weight loss of 15–17% body weight over 68 weeks. The SELECT trial showed a 20% reduction in major adverse cardiovascular events. Oral semaglutide (Rybelsus) is also FDA-approved for type 2 diabetes.
The SCALE clinical trial program demonstrated 5–10% body weight loss (Saxenda 3.0 mg). The LEADER trial showed cardiovascular benefit in type 2 diabetes patients. While effective, it produces less weight loss than semaglutide or tirzepatide. It is FDA-approved for pediatric obesity (ages 12+).
Semaglutide and Liraglutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs